

Date: 13.08.2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Unaudited Financial Result of the Company under Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the Quarter ended on 30th June, 2026

Company Scrip Code: 532167

Dear Sir(s),

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please find enclosed herewith:

1. Unaudited Financial Results of the Company, for the Quarter ended on 30th June, 2026, alongwith Limited Review Report of the company.

The aforesaid result has been approved by the Board of Directors at their meeting held on 13th August, 2026.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**



Bhawani S Goyal
(Managing Director)
DIN: 03255804
Address: Ward No-03, Nangal Chaudhry,
Narnaul, Mahendragarh, Haryana-123023

Encl: a/a

Limited Review Report to the Board of Directors of **Omkar Pharmachem Limited** for quarter ended on 30th June, 2026

We have reviewed the accompanying statement of unaudited financial results of **Omkar Pharmachem Limited** for the quarter ended on 30th June, 2026.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure




Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Dipal R. Shah & Co.

Chartered Accountants

ERN 126576W



(Dipal R. Shah)

Partner

UDIN: 26119628MDSUMC7339

Place: Ahmedabad

Date : 13/08/2026

Omkar Pharmachem Ltd.

Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30th June 2026

		(Rs. in lakh except per share data)			
Sr. No.	Particulars	Quarter Ended on			Financial Year ended on
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Part-I				
1	Income from operations				
	a) Net Sales/ Income from Operations	0.00	0.00	0.00	0.00
	b) Other Operating Income	9.00	9.00	13.50	46.50
		9.00	9.00	13.50	46.50
2	Other Income	0.00	0.30	0.00	0.74
3	Net Total income	9.00	9.30	13.50	47.24
4	Expenses				
	a) Cost of material consumed	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	5.14	5.14	4.93	20.86
	e) Finance Cost	0.00	0.00	0.00	0.21
	f) Depreciation and Amortization Expenses	0.04	0.08	0.08	0.33
	g) Other Expenses	4.82	2.13	4.91	9.56
	Total Expenses	10.00	7.35	9.92	30.96
5	Profit(Loss) before exceptional items and tax(3-4)	(1.00)	1.95	3.58	16.28
6	Exceptional items	0.00	0.00	0.00	0.00
7	Profit(Loss) from before Tax(5±6)	(1.00)	1.95	3.58	16.28
8	Tax Expense	0.00	0.45	0.92	4.10
9	Profit(Loss) for the period (7-8)	(1.00)	1.50	2.66	12.18
10	Other Comprehensive Income (Expense)	0.00	2708.43	0.00	2708.43
11	Total Comprehensive Income for the period (9±10)	(1.00)	2709.93	2.66	2720.61
12	Paid up Equity Share Capital (Face Value Rs. 10/- each)	1008.37	1008.37	1008.37	1008.37
13	Other equity		(52.82)		(52.82)
14	Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs.	(0.0099)	0.0149	0.0264	0.1208

Notes

- The above results have been reviewed by the audit committee & approved by the Board of Directors at their respective meeting held on 13th August 2026.
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
- The financial result for the Quarter ended on 30-06-2026 has been prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thereunder.
- The IND-AS regarding segment reporting is not applicable to the company.

By order of the Board

(Bhawani S Goyal)

Managing Director

DIN No. 03255804

Ward No- 03, Nangal Chaudhry, Narnaul,
Mahendragarh, Haryana-123023

Place: Ahmedabad

Date : 13-08-2026